These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23046522)

  • 1. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
    Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mining FDA drug labels using an unsupervised learning technique--topic modeling.
    Bisgin H; Liu Z; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2011 Oct; 12 Suppl 10(Suppl 10):S11. PubMed ID: 22166012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
    Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
    Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
    Yeh JS; Sarpatwari A; Kesselheim AS
    Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between the United States and Japan in labels of oncological drugs.
    Jayaputra K; Ono S
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles.
    Xu R; Wang Q
    J Biomed Inform; 2015 Feb; 53():128-35. PubMed ID: 25445920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
    Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
    Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
    J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.
    Wang K; Wan M; Wang RS; Weng Z
    J Med Internet Res; 2016 Apr; 18(4):e76. PubMed ID: 27036325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concept Modeling-based Drug Repositioning.
    Patchala J; Jegga AG
    AMIA Jt Summits Transl Sci Proc; 2015; 2015():222-6. PubMed ID: 26306277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning-based identification and rule-based normalization of adverse drug reactions in drug labels.
    Tiftikci M; Özgür A; He Y; Hur J
    BMC Bioinformatics; 2019 Dec; 20(Suppl 21):707. PubMed ID: 31865904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of drug network based on side effects and its application for drug repositioning.
    Ye H; Liu Q; Wei J
    PLoS One; 2014; 9(2):e87864. PubMed ID: 24505324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mining FDA drug labels for medical conditions.
    Li Q; Deleger L; Lingren T; Zhai H; Kaiser M; Stoutenborough L; Jegga AG; Cohen KB; Solti I
    BMC Med Inform Decis Mak; 2013 Apr; 13():53. PubMed ID: 23617267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.